The Future of Thyroid Eye Disease
What It Is
Thyroid Eye Disease is a progressive, vision threatening autoimmune inflammatory disease that attacks tissues behind the eye pushing the eye forward out of the socket. Importantly, this interaction occurs behind the eye and not within the eye itself. Patients constantly express how the impact of this disease is often overlooked or underestimated by others, but the reality is that this disease affects all aspects of their lives. On the exterior, everyone sees how patients suffer from obvious bulging eyes. However, most patients also suffer every day with proptosis (protruding eyes), strabismus (mis-aligned eyes), double and blurry vision, intense pain, distorted vision, permanent facial disfigurement and social isolation.
Teprotumumab is the first effective treatment for symptoms of Thyroid Eye Disease. More than a decade in the making, Teprotumumab addresses the physical symptoms of Thyroid Eye Disease including reduction in extra-ocular muscle size, elimination of pain, redness, vision issues and other disfigurements in the course of a 24-week treatment period. Patients have documented seeing results within 6 weeks, describing the treatment course like “watching the disease melt away.”
It is important to note that Teprotumumab is a treatment for Thyroid Eye Disease, but does not treat the thyroid condition or Graves’ Disease itself.
How It Works
Who Is a Candidate?
- Have thyroid eye disease in the active stage
- Does not require immediate surgical ophthalmological intervention
- Must not be pregnant or lactating